ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,918.25
0.16%
Dow Jones
42,635.20
0.25%
US Dollar vs MXN
20.40783
0.37%
Brent Oil
75.975
-1.41%
Bitcoin
94,482.16
-2.50%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Immunome Inc (IMNM) Cotización

Immunome Inc

Immunome Inc (IMNM)

NASDAQ
10.66
-0.10
(-0.93%)
Al cierre: 08 Enero 3:00PM
Delayed by 15 minutes
10.66
0.00
( 0.00% )
Fuera de horario: 3:29PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
10.66
Postura de Compra
10.27
Postura de Venta
11.09
Volume Operado de la Acción
334,640
10.35 Rango del Día 10.85
8.97 Rango de 52 semanas 30.958
Capitalización de Mercado [m]
665.364M
Precio Anterior
10.76
Precio de Apertura
10.72
Hora
9
@
10.35
Última hora de negociación
15:20:47
Volumen financiero
US$ 3,521,576
Precio Promedio Ponderado
10.5235
Volumen promedio (3 m)
810,027
Acciones en circulación
62,416,845
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-6.23
Beneficio por acción (BPA)
-1.71
turnover
14.02M
Beneficio neto
-106.81M

Acerca de Immunome Inc

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.immunome.com
Sede
Wilmington, Delaware, USA
Fundado
-
Immunome Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNM. The last closing price for Immunome was US$10.76. Over the last year, Immunome shares have traded in a share price range of US$ 8.97 to US$ 30.958.

Immunome currently has 62,416,845 shares in issue. The market capitalisation of Immunome is US$671.61 million. Immunome has a price to earnings ratio (PE ratio) of -6.23.

IMNM Últimas noticias

Más noticias

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

SAN FRANCISCO and SINGAPORE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat...

07 Enero 2025
GlobeNewswire Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025...

02 Enero 2025
Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 2, 2024...

02 Diciembre 2024
Business Wire

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome’s management will...

27 Noviembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

25 Noviembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

25 Noviembre 2024
Edgar (US Regulatory)

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

22 Noviembre 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

14 Noviembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

13 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

13 Noviembre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.04-0.37383177570110.711.610.4755611410.97419414CS
4-3.33-23.802716225913.9914.110.1184656511.26448819CS
12-1.62-13.192182410412.2815.1258.9781002711.52393452CS
26-1.46-12.046204620512.1216.818.9772034112.8220523CS
52-0.69-6.0792951541911.3530.9588.9776266615.44465275CS
156-1.02-8.7328767123311.6830.9582.0931503613.79577311CS
260-5-31.928480204315.6663.782.0928183415.72146231CS

IMNM - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Immunome?
El precio actual de las acciones de Immunome es US$ 10.66
¿Cuántas acciones de Immunome están en circulación?
Immunome tiene 62,416,845 acciones en circulación
¿Cuál es la capitalización de mercado de Immunome?
La capitalización de mercado de Immunome es USD 671.61M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Immunome?
Immunome ha negociado en un rango de US$ 8.97 a US$ 30.958 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Immunome?
El ratio precio/beneficio de Immunome es -6.23
¿Cuál es el ratio de efectivo a ventas de Immunome?
El ratio de efectivo a ventas de Immunome es 47.46
¿Cuál es la moneda de reporte de Immunome?
Immunome presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Immunome?
El último ingresos anual de Immunome es USD 14.02M
¿Cuál es el último beneficio anual de Immunome?
El último beneficio anual de Immunome es USD -106.81M
¿Cuál es la dirección registrada de Immunome?
La dirección registrada de Immunome es CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Immunome?
La dirección del sitio web de Immunome es www.immunome.com
¿En qué sector industrial opera Immunome?
Immunome opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
STAIScanTech AI Systems Inc
US$ 3.46
(58.72%)
1.55M
CHNRChina Natural Resources Inc
US$ 1.00
(33.85%)
4.47M
KAVLKaival Brands Innovations Group Inc
US$ 1.15
(17.35%)
3.14M
HOTHHoth Therapeutics Inc
US$ 2.15
(14.27%)
1.02M
DBVTDBV Technologies SA
US$ 4.295
(12.43%)
977.91k
XXII22nd Century Group Inc
US$ 5.90
(-26.80%)
413.49k
AVDLAvadel Pharmaceuticals PLC
US$ 8.65
(-19.16%)
56.4k
SYTASiyata Mobile Inc
US$ 7.08
(-17.77%)
52.45k
SILOSilo Pharma Inc
US$ 1.41
(-17.54%)
730.57k
IMGCIMG Inc
US$ 0.6934
(-14.38%)
215.26k
MBIOMustang Bio Inc
US$ 0.2554
(9.66%)
13.83M
CHNRChina Natural Resources Inc
US$ 0.99
(32.51%)
4.47M
XTIAXTI Aerospace Inc
US$ 0.0494
(-1.20%)
4.02M
KAVLKaival Brands Innovations Group Inc
US$ 1.1401
(16.34%)
3.14M
ESGEiShares Inc iShares ESG Aware MSCI EM ETF
US$ 33.4874
(0.08%)
3.06M

IMNM Discussion

Ver más
tw0122 tw0122 1 mes hace
Looking good in some reverse head and shoulders at .85+4% and  .92-.99 up next. The world of DNA
👍️0
Monksdream Monksdream 4 meses hace
IMNM under $15

👍️0
Monksdream Monksdream 10 meses hace
IMNM 10Q due 3/22
👍️0
Monksdream Monksdream 10 meses hace
IMNM new 52 week hi
👍️0
Monksdream Monksdream 12 meses hace
IMNM new 52 week high
👍️0
OncoJock OncoJock 1 año hace
Agree.

Wish there were most posts on this board.

Wondering who might be the next big customer to sign a major discovery and commercialization contract with IMNM, after AbbVie?

Also wondering if IMNM is doing any discovery/testing/research related to bispecific antibodies, as opposed to antibody-drug conjugates. Bispecifics are HOT HOT HOT in lymphoma and myeloma.

-- OJ
👍️0
OncoJock OncoJock 1 año hace
agree
👍️0
Laster Laster 1 año hace
Hopefully the vote passed.
I think this biotech combined company can be a huge success.
Siegall has proven he can build a biotech company.
This will be fun to watch.
👍️ 1
Laster Laster 1 año hace
I believe merger news tomorrow along with huge financing.
Clay B. Siegall To become chairman and CEO of combined company.
He founded Seagen which just sold for $40 billion to Pfizer.
Their innovative technology from Professor Philip S. Low (Purdue University).
Look at Professor Low accomplishments. Unreal.
Watching closely because this might become a huge biotech company.
👍️ 1
wiwineguy wiwineguy 2 años hace
Ha, sold in fall of 21 for $25.
👍️0
makinezmoney makinezmoney 2 años hace
$IMNM: Now 10.40 !!!!!!!!!!!

Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa


Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies



GO $IMNM
👍️0
makinezmoney makinezmoney 2 años hace
$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50


Offfffffffffff she goes.

Nice boomer



GO $IMNM
👍️0
Awl416 Awl416 2 años hace
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
👍️ 1
wiwineguy wiwineguy 3 años hace
you don't know crap majorbankz. you keep saying i "heard" this, and I "heard" that. can you be any more vague. stfu
👍️0
Harbor6460 Harbor6460 3 años hace
They cannot dilute on the bid. Only the ask
👍️0
Pedro2004 Pedro2004 3 años hace
Pulled down to under $20.00
👍️0
Pedro2004 Pedro2004 3 años hace
They pulled this down to under $21.00

I'm back-in at $21.00
👍️0
Major_Bankz Major_Bankz 3 años hace
$22.50 U worry too much, should be $25+ this afternoon IMO
👍️0
Pedro2004 Pedro2004 3 años hace
I thought this was going to break today. But it' just jumped over $22 -- let's see if that holds.
👍️0
Pedro2004 Pedro2004 3 años hace
This run could have broke $30 today. But the company killed-it.
👍️0
Major_Bankz Major_Bankz 3 años hace
yep, shorties portfolio will get destroyed here.
👍️0
Pedro2004 Pedro2004 3 años hace
The dilution is going to kill this run.
👍️0
Pedro2004 Pedro2004 3 años hace
Looks like the company is dumping shares on the bid.
👍️0
Major_Bankz Major_Bankz 3 años hace
I don't think PFE and MRNA can claim the same effectiveness for DELTA, plus time to buy is during development not after just like when MRNA was at $20. IMO
👍️0
Major_Bankz Major_Bankz 3 años hace
Delta is a BIG problem, IMNM may catch up to PFE and MRNA. IMO
👍️0
Major_Bankz Major_Bankz 3 años hace
Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.
👍️0
Major_Bankz Major_Bankz 3 años hace
IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
👍️0

Su Consulta Reciente

NASDAQ
IMNM
Immunome
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados